Human immunodeficiency virus type 1 (HIV-1) infection causes profound immunological
defects in afflicted patients. Various mechanisms have been proposed to account for the …

Human immunodeficiency virus type 1 (HIV-1) persists in a latent state within resting CD4 +
T cells of infected persons treated with highly active antiretroviral therapy (HAART). This …

The possibility of HIV-1 eradication has been limited by the existence of latently infected
cellular reservoirs. Studies to examine control of HIV latency and potential reactivation have …

The use of antiretroviral therapy in HIV type 1 (HIV-1)–infected patients does not lead to virus
eradication. This is due, to a significant degree, to the fact that HIV-1 can establish a highly …

Currently, amphotropic retroviral vectors are widely used for gene transfer into CD34+
hematopoietic progenitor cells. The relatively low levels of transduction efficiency associated with …

Retroviruses utilize cellular dNTPs to perform proviral DNA synthesis in infected host cells.
Unlike oncoretroviruses, which replicate in dividing cells, lentiviruses, such as human …

The therapeutic potential of pharmacologic inhibition of bromodomain and extraterminal (BET)
proteins has recently emerged in hematological malignancies and chronic inflammation. …

DNA damage is a universal inducer of cell cycle arrest at the G 2 phase. Infection by the human
immunodeficiency virus type 1 (HIV-1) also blocks cellular proliferation at the G 2 phase. …

Natural killer (NK) cell degranulation in response to virus-infected cells is triggered by interactions
between invariant NK cell surface receptors and their ligands on target cells. Although …

… This work was supported by NIH grant AI087508 to Vicente Planelles. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the …